The novel monoclonal immunoglobulin, Pritoxaximab – formerly known as DXX00601 – represents significant promise within the treatment of critical hemolytic disease (TRALI). Engineered by Bio-X, Pritoxaximab works by https://socialmediainuk.com/story28085260/pritoxaximab-a-deep-dive-into-dxx00601-s-potential